We prospectively evaluated the surgical, audiologic, and quality-of-life outcomes in 5 patients-2 men and 3 women, aged 22 to 64 years (mean: 41.8)-who were implanted with the Sophono Alpha 2 MPO Processor. The indications for implantation of this bone-conduction device included recurrent ear canal infections with hearing aids (n = 3), single-sided deafness (n = 1), and patient preference in view of difficulty using a conventional hearing aid (n = 1). In addition to the patient with single-sided deafness, 3 patients had a bilateral mixed hearing loss and 1 had a bilateral conductive hearing loss. Outcomes measures included surgical complications, functional gain (FG), speech discrimination in quiet and noise, and patient satisfaction as determined by the Glasgow Benefit Inventory (GBI) and the Entific Medical Systems bone-anchored hearing aid questionnaire (BAQ). The only postsurgical complication noted was a minor skin reaction and pain in 1 patient that resolved with conservative management. In the 3 patients with the mixed hearing loss, the mean FG was 13.3, 20.0, 11.7, and 11.7 dB at 0.5, 1, 2, and 4 kHz, respectively; in the patient with the bilateral conductive hearing loss, the FG was 10, 25, 10, and 15 dB at the same frequencies.
Introduction
Bone-anchored hearing aids (BAHAs) have been in use for more than 30 years. 1, 2 Their efficacy in the management of hearing-impaired patients with a mixed or conductive hearing loss who are unable to use conventional hearing aids has been well established. 3 The early percutaneous devices (Baha; Cochlear; Sydney, Australia, and Ponto; Oticon; Smørum, Denmark) propagate sound through an osseointegrated implant. 1 Indications for these devices include malformations of the middle and external ear, chronic discharge, ossicular chain disease, and single-sided deafness. 4 There are, however, a number of drawbacks to the percutaneous devices.
The most common implant complication is a periabutment soft-tissue reaction, as classified by Holgers et al. 5 Other complications include chronic pain, infection, and implant loss. 4 In a study of more than 1,000 implants, Dun et al found an implant loss rate of 8.3% over an average of 10 years of follow-up. 6 The next advancement was transcutaneous BAHAs, which conduct sounds by magnetic coupling across intact skin. 7, 8 Their indications are similar to those of the percutaneous devices, but they have different advantages and disadvantages. For example, transcutaneous devices require no skin-penetrating abutment, so the risk of skin complications and implant loss is reduced. 7, 8 Audiologic outcomes with transcutaneous devices reported in the literature have been variable; they appear to depend on the type of hearing loss. [8] [9] [10] On the other hand, transcutaneous bone-conduction systems have been shown to result in less functional gain (FG) than the osseointegrated percutaneous devices; this is attributable to skin attenuation. 7, 10 One of the transcutaneous implants currently available is the Sophono system (Medtronic; Boulder, Colo.) developed by Siegert. 7 This system consists of a surgically implanted plate that contains two magnets affixed to the skull and an external sound processor that houses a bone oscillator and a metal disc. This arrangement allows for magnetic coupling of the internal and external components across intact skin.
In this article, we describe our study of the surgical, audiologic, and quality-of-life outcomes with the use of the Sophono implant.
Patients and methods
We prospectively studied 5 patients-2 men and 3 women, aged 22 to 64 years (mean: 41.8)-who were implanted with a Sophono Alpha 2 MPO Processor from May 2012 through April 2013 (table 1) . The surgeries were carried out by a single surgeon (M.G.) at two institutions, the Monash Medical Centre and the Masada Private Hospital, both in Melbourne, Australia.
Outcomes measures included surgical complications, FG, speech discrimination in quiet and noise, and quality of life.
Audiologic assessments. Audiologic testing was carried out by a single audiologist (A.P.) preoperatively and again postoperatively at the time of activation. Pure-tone thresholds for air and bone conduction were measured at 0.5, 1, 2, and 4 Hz pre-and postoperatively. The implant was activated about 6 weeks after surgery (range: 35 to 58 days; mean: 45).
The first postoperative soundfield testing with warble tone was conducted with the sound presented at an azimuth of 0° in the Sophono-aided condition. The FG provided by the Sophono device was calculated by subtracting the optimally aided soundfield threshold from the unaided postoperative pure-tone air-conduction threshold at each frequency.
Speech discrimination testing was performed with AB (Arthur Boothroyd) word lists in both quiet and noise at 60 dB SPL, and comparisons were made between the pre-and postoperative scores. The testing conditions were kept as close as possible to each patient's usual aided status in everyday life, especially for the contralateral ear, which was either unaided or aided with a conventional hearing aid or a BAHA.
Subjective assessments. Quality of life was determined by the results of the Glasgow Benefit Inventory (GBI) and the Entific Medical Systems bone-anchored hearing aid questionnaire (BAQ):
• The GBI is designed to gauge changes in health status that occur as a result of a surgical intervention. It consists of three subscales: general (6 items), social (3 items), and physical (3 items). There are 5 possible responses to each subscale question. Results are based on the total score, which ranges from -100 (no benefit) to +100 (maximum benefit).
• The BAQ includes two sections, preoperative and postoperative. The preoperative section consists of 12 items relating to qualitative and quantitative aspects of a patient's hearing status at baseline. The postoperative section contains 8 items regarding the results of implantation. In both cases, patients rate their satisfaction with their hearing device on a scale of 1 (very unsatisfied) to 10 (very satisfied).
With both assessment tools, postoperative tests were administered after at least 2 weeks of consistent device use. Surgical technique. For implantation of the Sophono device, a curvilinear incision line was marked posterosuperior to the pinna (figure 1, A). After infiltration of local anesthesia, an incision was made down to and including the pericranium. An anteriorly based flap was elevated, and the position of the implant was marked. A double well was then drilled into the skull cortex ( figure 1, B) to accommodate the twin-magnet implant (figure 1, C). The implant was then secured into place with five self-drilling screws.
The flap was replaced and the wound was closed in layers. Once the wound and flap healed (figure 1, D), the electronic sound processor and external magnet were loaded, usually about 4 weeks after surgery.
Results
Preoperative findings. All patients had a bilateral hearing loss, the severity of which varied among patients. One of the 5 patients had single-sided deafness on the implanted side and a mild mixed hearing loss in the other ear (patient 1); he was unaided. Three patients had a bilateral mixed hearing loss (patients 2, 4, and 5); 2 of them used a conventional hearing aid in both ears, while the third had a BAHA on the contralateral side only. Finally, 1 patient had a bilateral conductive hearing loss (patient 3); she used a conventional hearing aid in both ears. The indications for Sophono implantation included recurrent ear canal infections (n = 3), single-sided deafness (n = 1), patient preference in view of difficulty using a conventional hearing aid (n = 1) (table 1) .
Preoperatively, the patient with single-sided deafness had a mean air-conduction threshold of 28.8 dB HL and a mean bone-conduction threshold of 18.8 dB HL in the contralateral ear. In the 3 patients with a bilateral mixed hearing loss, the mean preoperative air-conduction threshold was 60.0 dB HL (range: 52.5 to 72.5) and the mean bone-conduction threshold was 30.0 dB HL (range: 23.8 to 36.3) on the implanted side. The patient with the bilateral conductive loss had a mean air-conduction threshold of 53.8 dB HL and a mean bone-conduction threshold of 20.0 dB HL on the implanted side (table 2) .
Surgical complications. We observed no major surgical complications. One patient experienced a minor skin reaction and pain in the early postoperative period, which both resolved with conservative management.
Functional gain. The FG for the patient with single-sided deafness could not be calculated because of the nature of his hearing loss. However, he did experience an improvement in soundfield thresholds of 25, 10, and 5 dB at 0.5, 1, and 2 kHz, respectively.
In the 3 patients with a mixed hearing loss, the mean FG was 13.3, 20.0, 11.7, and 11.7 dB at 0.5, 1, 2, and 4 kHz respectively. The mean across all four frequencies was 14.2 dB (table 3) .
In the patient with bilateral conductive hearing loss, the FG was 10, 25, 10, and 15 dB at 0.5, 1, 2, and 4 kHz. The mean across all frequencies was 15.0 dB (table 3) .
Among the 4 patients with a bilateral mixed or conductive hearing loss, the mean FG across all frequencies was 14.4 dB, with little difference between the mixed and conductive hearing loss patients. Speech discrimination. In all 5 patients, the postoperative Sophono-aided speech discrimination scores as assessed with the AB word list were comparable to the preoperative scores in both quiet and noise, although performance deteriorated with increasing background noise ( figure 2) .
Subjective assessments. The mean GBI scores in the three subscales (general, social, and physical) were +29.2, +13.3, and +20.0, respectively, and the mean total score was +24.4 (table 4). All patients reported an overall positive outcome, with the most improvement seen in the general subscale.
The preoperative BAQ scores were mixed, with some patients reporting that their conventional hearing aids were "difficult to use," "uncomfortable," and "not very helpful," while others found them "easy to use" and "invaluable." Postoperatively, 2 patients found that speech discrimination improved with the implant while the other 3 said it had not changed. Four patients believed that the aesthetics had improved while 1 felt that they were worse. Two patients found that usability improved and 3 said it was no different from the old device. The average global satisfaction BAQ scores were 6.2 of a possible 10 for the preoperative aided condition and 7.4 with the Sophono implant.
Throughout follow-up, all patients remained satisfied with their implant and said that they wore their device every day for more than 8 hours.
Discussion
We observed only one minor transient postoperative complication with the Sophono device, which is consistent with similarly low complication rates published in the literature. In a study by Siegert, the originator of the device, about 4% of patients developed temporary pressure areas, which were resolved by adjusting the magnet strength. 7 According to that report, patients expressed overall improvements in comfort and safety compared with percutaneous devices. Sylvester et al also found a low complication rate, as 10% of their patients experienced a minor skin irritation that resolved with magnet adjustment. 8 In contrast, percutaneous BAHAs are associated with much higher complication rates. In a study of more than 600 BAHAs, Hobson et al reported an overall complication rate of 23.9%. 11 Revision surgery was required in 12.1% of cases. Their findings were well within the complication rates of 8 to 59% they found in the literature.
Overall, the audiologic outcomes for patients using the Sophono device in our study were positive. The 3 patients with a bilateral mixed hearing loss had a mean FG of 14.2 dB across all frequencies, which was greater than the 6 dB reported by Sylvester et al. 8 Adding the 8 In a case series of 6 children with congenital atresia, Denoyelle et al found that the FG with the Sophono device was as high as 43 dB. 9 In a study of 12 children, Hol et al compared the outcomes of the Sophono device with those of the Baha device and concluded that while both systems provided audiologic benefits, the Baha device yielded slightly better outcomes in terms of soundfield thresholds, speech recognition threshold, and speech comprehension, and its output was 10 to 15 dB higher. 10 Most studies published to date have found that use of the Sophono system improved speech discrimination or speech reception threshold relative to the unaided condition. [8] [9] [10] In our study, the speech discrimination outcome with Sophono was found to be at least comparable to that of conventional hearing aids.
Our patients expressed overall satisfaction with the Sophono device, especially compared with their previous hearing aid. Overall, their satisfaction score on the BAQ before and after implantation rose from 6.2 to 7.4. We also found positive outcomes according to the GBI, with the mean overall score of +24.4. This is similar to the positive results seen with respect to other ENT operations measured by the GBI. For example, Gatehouse reported benefits of +24 after rhinoplasty and +27 after tonsillectomy, with the latter reflecting an improvement but not complete cure of symptoms. 12 Similarly, Denoyelle et al found that children and parents were either satisfied or very satisfied with the Sophono system. 9 One notable case in this series was a 22-year-old man (patient 5) who was blind and who already had a BAHA on the contralateral side. He reported that the Sophono processor was easier to place than the BAHA, and that the lack of a percutaneous abutment that required daily maintenance was a big advantage. His case illustrates the importance of assessing individual patients' capabilities and taking into consideration any disabilities they may have when choosing an implant.
Our study had a number of limitations. The patient population was small, and the cohort was heterogeneous, particularly with respect to the different types of hearing loss, which made it difficult to draw any firm conclusions regarding each type of hearing loss. The hearing status of the patient with single-sided deafness (patient 1) was slightly outside the implantation guidelines, as the mean air-conduction threshold was 28.8 dB HL in his good-hearing ear. Nevertheless, we believe that our rigorous prospective audiologic and quality-of-life data collection provides useful information on this relatively new device.
We conclude that the Sophono Alpha 2 MPO Processor bone-conduction system is a safe and efficacious option that should be considered in patients with a mixed or conductive hearing loss who are unable to use a conventional hearing aid, as well as for those with single-sided deafness. Transcutaneous stimulation has clear advantages over percutaneous stimulation in terms of aesthetics and complication rates. It does, however, provide a lower audiologic output than a BAHA, and it is therefore important to carefully consider both patient and audiologic factors for best outcomes. 
